PLAN B 1.5 MG
LEVONORGESTREL : 1.5 MG · DIN 02293854 · FOUNDATION CONSUMER HEALTHCARE, LLC
Health Canada status: MARKETED
What is PLAN B?
PLAN B 1.5 MG contains LEVONORGESTREL : 1.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02293854, held by FOUNDATION CONSUMER HEALTHCARE, LLC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PLAN B used for?
Emergency contraception to prevent pregnancy when used within 72 hours of unprotected intercourse or known/suspected contraceptive failure. Not for routine use.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02293854 |
|---|---|
| Brand name | PLAN B |
| Generic / active ingredient | LEVONORGESTREL : 1.5 MG |
| Manufacturer | FOUNDATION CONSUMER HEALTHCARE, LLC |
| Strength | 1.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | G03AD01 LEVONORGESTREL |
| AHFS class | 68:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 11-Oct-2018 |
| Original market date | 2015-07-23 00:00:00 |
How is it administered?
One 1.5 mg tablet taken orally as soon as possible but within 72 hours after unprotected intercourse. If vomiting occurs within 2 hours of dosing, a replacement dose may be warranted.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text snippet (section 11 is in the TOC but text ends at section 8.3). Standard manufacturer's storage usually applies.
How is it supplied?
PVC/aluminum foil blister packages of one tablet each, contained in a four-panel outer package sealed with shrink-wrap.
Contraindications
Hypersensitivity to levonorgestrel or any ingredient; known or suspected pregnancy; undiagnosed abnormal vaginal bleeding.
Warnings and precautions
Provides no protection against HIV/STIs. Not for routine use. Monitor for ectopic pregnancy if pregnancy occurs or abdominal pain develops. Reduced efficacy may occur with high BMI.
What can be used instead?
Other Canadian products sharing ATC code G03AD01 LEVONORGESTREL. 4 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BACKUP PLAN ONESTEP | 1.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02433532 |
| CONTINGENCY ONE | 1.5 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02425009 |
| MYSTEP | 1.5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02548461 |
| BACKUP PLAN | 0.75 MG | TABLET | APOTEX INC | CANCELLED PRE MARKET | DIN 02430177 |
| CONTINGENCY | 0.75 MG | TABLET | JAI PHARMA LIMITED | CANCELLED PRE MARKET | DIN 02410230 |
| LEVONORGESTREL TABLETS, 0.75MG | 0.75 MG | TABLET | LUPIN LIMITED | CANCELLED PRE MARKET | DIN 02431033 |
| NEXT CHOICE | 0.75 MG | TABLET | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | DIN 02364905 |
| NORLEVO | 0.75 MG | TABLET | LABORATOIRE HRA PHARMA | CANCELLED POST MARKET | DIN 02285576 |
| NORLEVO | 1.5 MG | TABLET | LABORATOIRE HRA PHARMA | APPROVED | DIN 02322919 |
| OPTION 2 | 0.75 MG | TABLET | PERRIGO INTERNATIONAL | CANCELLED POST MARKET | DIN 02371189 |
Who else supplies LEVONORGESTREL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVONORGESTREL appears in 18 registered pack listings across 3 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.